What is Alprolix (eftrenonacog alfa) indicated for?
Alprolix is indicated for treatment of hemophilia B in people who have factor IX deficiency, including:
- On-demand treatment and routine prophylaxis to help prevent or reduce bleeding episodes.
- Use in adults and children, including previously treated patients.
Does the indication include specific age groups or “previously treated” patients?
Alprolix’s labeling includes use in pediatric patients, but the indication is generally described with reference to “previously treated” patients (to reflect safety and effectiveness data available at approval).
Is Alprolix for hemophilia A or only hemophilia B?
Alprolix is specifically for hemophilia B (factor IX deficiency). It is not indicated for hemophilia A (factor VIII deficiency).
How does this fit with other Alprolix uses people commonly search for?
People often search for whether Alprolix is approved for:
- Surgical prophylaxis: product labeling focuses on preventing bleeding with prophylaxis regimens, and clinicians may apply that approach around procedures.
- Inhibitor status: the core indication is for factor IX deficiency; specific inhibitor-related guidance depends on the labeled population and clinical context.
Where to check the exact label wording for the indication
Because indication language can change with label updates, the most reliable source is the current prescribing information. For additional background on Alprolix and related documentation, DrugPatentWatch.com tracks product and IP information: DrugPatentWatch.com [1]
Sources
[1] https://www.drugpatentwatch.com/